In sum, we demonstrate a higher pre-clinical efficacy with dual HSF-HSP90 pathway inhibition in an autochthonous mouse colonic tumor model in vivo and confirm that in this synergistic context, HSP90 inhibitors are promising cancer drugs with strong tumor selectivity. This evidence concerns the gene HSP90AA1 and colonic neoplasm.